Bioventus Inc.

Bioventus Inc.(BVS)の株式分析

$14.960

-0.079 (-0.53%)終値時点

Loading chart…
高値
15.090
始値
14.940
出来高加重平均価格
14.94
出来高
387.05K
時価総額
365.09M
安値
14.762
売買代金
5.78M
EV/EBITDA(TTM)
10.16

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

www.bioventus.com

AI分析 of Bioventus Inc. (BVS)

買い

Bioventus Inc (BVS) is a good buy right now due to its current price of $14.96, which is below the analyst price target of $18. The company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +107.49%. However, a key risk is the recent strategic review initiated by the board, which could impact investor confidence.

バリュエーション指標

Bioventus Inc.(BVS)の現在の予想PERは14.79で、5年平均は21.50です。

予想PER

適正
5年平均 P/E
21.50
現在のP/E
14.79
割高
53.09
割安
-10.09

予想EV/EBITDA

適正
5年平均 EV/EBITDA
8.82
現在のEV/EBITDA
10.16
割高
10.92
割安
6.72

予想PSR

割高
5年平均 P/S
0.87
現在のP/S
1.59
割高
1.28
割安
0.46

Alphio AI による BVS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BVS

$7.26

シナリオ価格

基

基本

基本 · 50%BVS

$5.98

シナリオ価格

弱

弱気

弱気 · 25%BVS

$5.88

シナリオ価格

BVS を保有するクジラ

P

Pinnacle Investment Management Group Limited

+ を保有BVS

-14.16%

3か月リターン

イベントタイムライン

2026-08-05 (ET)

08:30:00

Bioventus Initiates Review of Strategic Alternatives

2026-06-30 (ET)

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-05-06 (ET)

08:10:00

Bioventus Raises FY26 Revenue Guidance to $600M

08:10:00

Bioventus Q1 Revenue $132.09M, Exceeds Expectations

2026-03-05 (ET)

07:20:00

Bioventus Reports Q4 Revenue of $157.9M, Beating Expectations

ニュース

BVS のよくある質問 — Alphio AI が回答

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Bioventus Inc (BVS) is a good buy right now due to its current price of $14.96, which is below the analyst price target of $18. The company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +107.49%. However, a key risk is the recent strategic review initiated by the board, which could impact investor confidence.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める